Novellus is advancing a portfolio of engineered cell therapy programs to address multiple inflammatory, autoimmune, and neurologic indications.


Novellus’s product candidates must proceed through several stages of preclinical and clinical development before receiving marketing authorization. Our pipeline includes several wholly controlled product candidates, as well as one product candidate under development as part of a strategic alliance. All of our therapeutic programs are designed for safety, availability, and cost-effectiveness for patients.

Candidate Indication(s) Target Selection Research Preclinical Ind-Enabling Clinical Partner
NV-001 Acute Respiratory Distress Syndrome (ARDS), including COVID-19 (Partnered)
NV-002 Multiple Sclerosis (MS)
NV-003 Ulcerative Colitis/Crohn’s Disease
NV-004 Undisclosed
NV-005 Multiple Undisclosed

NoveCellsTM Engineered Cell Therapies

NoveCells™ are “off-the-shelf” allogeneic cell therapy product candidates produced from perpetual master cell banks derived from a single donor. NoveCells™ are made using mRNA cell reprogramming and mRNA gene editing, enabling efficient, scalable manufacturing and consistent batch-to-batch product characteristics.


Novellus engineers cells using mRNA cell reprogramming and mRNA gene editing technologies. Messenger RNA (mRNA) is a molecule that, like DNA, encodes information that cells can translate into proteins, but unlike DNA, cannot create unwanted mutations in the cell’s genome. We use mRNA to induce somatic cells from a single donor to dedifferentiate into a pluripotent stem cell state. These pluripotent stem cells can be expanded and differentiated to create a near-unlimited supply of therapeutic cells with uniform characteristics that are tailored to patient needs.